Cue Biopharma
Repositioning a precision immunotherapies company that transforms patients’ lives.
CASE STUDY / CUE BIOCue Biopharma was at a pivotal moment. Leadership recognized the need to evolve brand perceptions from a cancer R&D lab to a biopharma company bringing viable immunotherapies to clinical study and, eventually, to patients.
Cue’s unique science was exceptionally smart, so much so that they struggled to tell their story clearly and simply enough to convey value to investors and partners. Over a several-year engagement, we worked to unveil their scientific story and its value, and to project cutting-edge perceptions into the industry.
Services
Brand Strategy
Visual Identity
Medical Illustration
Web Design + Development
Corporate Communications
BRAND VISUAL IDENTITYThe Cue Visual Identity was inspired by the genomic engineering and cell biology discoveries at the heart of the biotech. The brand is built on a brilliant color palette, which also amplifies the structure of their discovery series.
MEDICAL ILLUSTRATIONSThe narrative behind the science came to life in a series of custom scientific renderings. These illustrations feature mechanisms in action at the cellular level, demonstrating clarity of science for the biopharma and investment communities.
WEB DESIGN + DEVELOPMENTWe extended the new visual identity to a redesigned Cue Bio website. The site is designed to mirror the brand’s upgraded aesthetic while also being technically sound, responsive, and search-optimized.
CORPORATE COMMUNICATIONS The brand’s strategy and visual identity were extended to corporate storytelling across many other communications. Working with their leadership and scientific teams, we unveiled the detail of scientific discoveries and the mechanisms of action of Cue’s investigational molecules.
A corporate presentation deck, business templates, scientific posters, and annual reports were all elevated to match.
WRAP-UP Our work with Cue Bio extended two-plus years under their founding CEO and beyond. Together we moved the brand past stagnant perceptions of their work in the cancer T-cell therapy space, demonstrating the company as a high-value pioneer in the immunotherapy.